Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bavituximab + carboplatin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Avid Bioservices
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bavituximab + carboplatin + paclitaxel is a combination regimen used in oncology clinical trials, particularly for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and breast cancer. Bavituximab is a phosphatidylserine-targeting chimeric monoclonal antibody that modulates the immune response and targets tumor vasculature by binding to phosphatidylserine exposed on tumor blood vessels, thereby promoting antitumor immunity and vascular disruption. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. The combination aims to leverage the immune-modulating effects of bavituximab with the cytotoxic actions of carboplatin and paclitaxel for enhanced antitumor efficacy[1][2][3][4].
- Brand names
- CarboTaxol
- Other names
- PC
02
Targets
DNAB2GP1 (Beta-2-glycoprotein I)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bavituximab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bavituximab + carboplatin + paclitaxel.